Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Sponsor: Novartis Pharmaceuticals
Listed as NCT01947608, this observational or N/A phase trial focuses on Non-small Cell Lung Cancer (NSCLC) and remains ongoing. Sponsored by Novartis Pharmaceuticals, it has been updated 19 times since 2026, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
19 versions recorded-
Nov 2025 — Present [monthly]
No Longer Available
-
Sep 2025 — Nov 2025 [monthly]
No Longer Available
-
Sep 2024 — Sep 2025 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
▶ Show 14 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Feb 2020 — Dec 2020 [monthly]
Available
-
Aug 2019 — Feb 2020 [monthly]
Available
-
Jun 2019 — Aug 2019 [monthly]
Available
-
Jan 2019 — Jun 2019 [monthly]
Available
-
Oct 2018 — Jan 2019 [monthly]
Available
-
Aug 2018 — Oct 2018 [monthly]
Available
-
Jul 2018 — Aug 2018 [monthly]
Available
-
Jun 2018 — Jul 2018 [monthly]
Available
-
Apr 2018 — Jun 2018 [monthly]
Available
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Available NA
-
Aug 2017 — Feb 2018 [monthly]
Available NA
-
Feb 2017 — Aug 2017 [monthly]
Available NA
-
Jan 2017 — Feb 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amman, Jordan , Atlanta, United States , Baltimore, United States , Bangkok, Thailand , Boston, United States , Buenos Aires, Argentina , Bundang Gu, South Korea , CABA, Argentina , Cali, Colombia , Chandler, United States and 33 more locations